The price of Aptose Biosciences Inc. (NASDAQ:APTO) shares last traded on Wall Street rose 2.67% to $0.71.
As we calculate the median target price by taking the range between a high of $13.00 and a low of $3.00, we find $6.00. Given the previous closing price of $0.69, this indicates a potential upside of 769.57 percent. APTO stock price is now 11.87% away from the 50-day moving average and -9.96% away from the 200-day moving average. The market capitalization of the company currently stands at $61.26M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Brokers who have rated the stock have averaged $7.57 as their price target over the next twelve months.
With the price target of $10, Cantor Fitzgerald recently initiated with Overweight rating for Aptose Biosciences Inc. (NASDAQ: APTO). On September 22, 2020, Alliance Global Partners recently initiated its ‘Buy’ rating on the stock quoting a target price of $12, while ‘Maxim Group’ rates the stock as ‘Buy’.
In other news, Rice William G., Chair, President & CEO bought 10,000 shares of the company’s stock on Sep 19. The stock was bought for $6,834 at an average price of $0.68. Upon completion of the transaction, the Chair, President & CEO now directly owns 363,252 shares in the company, valued at $0.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 19, SR VP & Chief Fin. Officer Payne Fletcher bought 10,000 shares of the business’s stock. A total of $6,775 was incurred on buying the stock at an average price of $0.68. This leaves the insider owning 10,000 shares of the company worth $7100.0. A total of 20.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APTO stock. A new stake in Aptose Biosciences Inc. shares was purchased by DRW SECURITIES, L.L.C. during the first quarter worth $6,296,000. VIRTU FINANCIAL LLC invested $23,000 in shares of APTO during the first quarter. In the first quarter, WARBERG ASSET MANAGEMENT LLC acquired a new stake in Aptose Biosciences Inc. valued at approximately $8,000. PDS PLANNING, INC acquired a new stake in APTO for approximately $7,000. ALMANACK INVESTMENT PARTNERS, LLC. purchased a new stake in APTO valued at around $2,000 in the second quarter. In total, there are 54 active investors with 35.10% ownership of the company’s stock.
A candlestick chart of Aptose Biosciences Inc. (NASDAQ: APTO) showed a price of $0.7000 on Tuesday morning. During the past 12 months, Aptose Biosciences Inc. has had a low of $0.43 and a high of $1.55. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.50, and a quick ratio of 5.50. The fifty day moving average price for APTO is $0.6336 and a two-hundred day moving average price translates $0.7871 for the stock.
The latest earnings results from Aptose Biosciences Inc. (NASDAQ: APTO) was released for Jun, 2022.
Aptose Biosciences Inc.(APTO) Company Profile
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
